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Leiden, Zwolle, Utrecht, The NetherlandsBackground and Aims: To optimize therapeutic decision-making in early invasive colorectal cancer (T1 CRC)
patients, it is important to elicit the patient’s perspective next to considering medical outcome. Because empirical
data on patient-reported impact of different treatment options are lacking, we evaluated patients’ quality of life,
perceived time to recovery, and fear of cancer recurrence after endoscopic or surgical treatment for T1 CRC.
Methods: In this cross-sectional study, we selected patients with histologically confirmed T1 CRC who partici-
pated in the Dutch Bowel Cancer Screening Programme and received endoscopic or surgical treatment between
January 2014 and July 2017. Quality of life was measured using the European Organization for Research and Treat-
ment 30-item Core Quality of Life Questionnaire and the 5-level EuroQoL 5-dimension questionnaire. We used
the Cancer Worry Scale (CWS) to evaluate patients’ fear of cancer recurrence. A question on perceived time to
recovery after treatment was also included in the set of questionnaires sent to patients.
Results: Of all 119 eligible patients, 92.4% responded to the questionnaire (endoscopy group, 55/62; surgery
group, 55/57). Compared with the surgery group, perceived time to recovery was on average 3
months shorter in endoscopically treated patients after adjustment for confounders (19.9 days vs 111.3 days;
P Z .001). The 2 treatment groups were comparable with regard to global quality of life, functioning domains,
and symptom severity scores. Moreover, patients in the endoscopy group did not report more fear of cancer
recurrence than those in the surgery group (CWS score, 0-40; endoscopy 7.6 vs surgery 9.7; P Z .140).
Conclusions: From the patient’s perspective, endoscopic treatment provides a quicker recovery than sur-
gery, without provoking more fear of cancer recurrence or any deterioration in quality of life. These results
contribute to the shared therapeutic decision-making process of clinicians and T1 CRC patients. (Gastrointest
Endosc 2019;89:533-44.)(footnotes appear on last page of article)With the introduction of population-based screening
programs in several countries, the proportion of patients
diagnosed with early invasive colorectal cancer (T1 CRC)
has vastly increased.1 Currently, therapeutic decision-
making for these patients is mainly based on oncologicUse your mobile device to scan this
QR code and watch the author in-
terview. Download a free QR code
scanner by searching “QR Scanner”
in your mobile device’s app store.
urnal.orgoutcomes and the risk of treatment-related adverse
events.2 Because cancer care has shifted from a disease-
based to a patient-centered approach, more attention is
being paid to functional outcomes and impact on quality
of life (QoL) of different treatment modalities.3
Approximately 6% to 12% of patients with T1 CRC
have lymph node metastases (LNM) at the time of diag-
nosis.4-6 These patients benefit from surgical treatment,
because surgery allows adequate lymph node dissection.
Histologic high-risk features associated with the pres-
ence of LNM include deep submucosal invasion (Haggitt
level 4 or Kikuchi level Sm2 or 3), positive resection mar-
gins, poor differentiation, presence of lymphatic orVolume 89, No. 3 : 2019 GASTROINTESTINAL ENDOSCOPY 533
Patient-reported impact of different treatment options for T1 CRC Dang et alvascular invasion, and tumor budding.7-9 However, in the
absence of these features, T1 CRCs carry a relatively low
risk of LNM (.8%).8 In these cases, endoscopic resection
is considered to be sufficient because the LNM risk does
not outweigh the risk of adverse events after surgical
resection.
When the aforementioned histologic criteria are used,
it remains difficult to accurately predict the presence of
LNM. Negative lymph nodes are found in about 80% of
all patients referred for surgical resection, indicating that
surgery has not provided additional oncologic benefit in
these cases.7 In addition, colorectal surgery involves a
significant risk of morbidity (30%) and even mortality
(1%-5%), especially in the elderly population,10-12 the
main target group of screening programs.13,14 On the con-
trary, therapeutic colonoscopies, including endoscopic
resection of large colon polyps,15,16 carry a low risk of
morbidity and mortality and are therefore considered to
be safe in the elderly.17 Because an accurate weighing
up of oncologic benefit versus the risk of treatment-
related adverse events remains challenging, eliciting the
patient’s perspective becomes especially important. In
other words, optimal decision-making in T1 CRC patients
involves balancing the aforementioned factors as well as
considering relevant patient-reported outcomes such as
QoL, fear of cancer recurrence, and perceived time to
recovery.
Although many studies have evaluated the QoL of pa-
tients after surgery for CRC,18-25 little is known about the
impact of endoscopic tumor resection on QoL. It is often
assumed that endoscopic treatment results in a better
overall QoL than colorectal surgery because endoscopy is
less invasive and preserves the functional integrity of the
colon or rectum.26,27 However, endoscopic treatment re-
quires a more intensive follow-up program.28 This may
provoke more fear of cancer recurrence and adversely
influence QoL because patients are more frequently
confronted with the risk of cancer recurrence. To the
best of our knowledge, simultaneous evaluation of QoL,
patients’ perceived time to recovery, and fear of cancer
recurrence after endoscopic or surgical treatment for T1
CRC has not been reported yet. Therefore, the aim of
our study was to compare the QoL, perceived time to
recovery, and fear of cancer recurrence between
endoscopically and surgically treated T1 CRC patients.METHODS
Patients
In this cross-sectional, 2-center study, patients were
selected according to the following inclusion criteria: (1)
participated in the Dutch Bowel Cancer Screening Pro-
gramme, (2) diagnosed with T1 CRC (defined as histologic
tumor invasion through the muscularis mucosa and into,
but not beyond, the submucosa), (3) received either endo-534 GASTROINTESTINAL ENDOSCOPY Volume 89, No. 3 : 2019scopic or surgical treatment at Leiden University Medical
Centre or Isala Hospital, Zwolle between January 1, 2014
and August 1, 2017, and (4) provided written informed
consent. Exclusion criteria were distant metastasis at time
of diagnosis, synchronous colorectal carcinomas else-
where, tumor down-staging by neoadjuvant therapy, and
unable to read Dutch. The study protocol was approved
by the Medical Ethical Committees of the 2 participating
centers (Leiden University Medical Centre [P16.269] and
Isala Hospital, Zwolle [170917]).Clinical characteristics
Clinical baseline characteristics (sex, age, comorbidity,
body mass index, prior abdominal surgery) and clinical
data (tumor size, morphology, and location; treatment-
related parameters; histology of the resected specimens;
endoscopic and imaging follow-up) were retrieved from
medical records. Patients’ family history of CRC as well
as data on marital and employment status were collected
through self-reporting questionnaires. Patient comorbidity
was quantified using the Charlson Comorbidity Index29
and the American Society of Anesthesiologists physical
status classification system.
For the endoscopically treated group, treatment-related
parameters were indication for endoscopic treatment,
method of resection, and treatment-related adverse events.
For the group that underwent surgery, treatment-related pa-
rameters were type of surgery, number of retrieved lymph
nodes, use of colostomy, indication for surgery, whether or
not prior endoscopic resection was performed, and
treatment-related adverse events. Patients treated with
transanal endoscopic microsurgery (TEM) were classified as
endoscopically treated patients, because only a local tumor
excision without lymph node dissection was performed.QoL questionnaires
Global QoL status was measured using the validated
Dutch version of the 5-level EuroQoL 5-dimension ques-
tionnaire (EQ-5D-5L).30,31 The first part of this instru-
ment is a 5-item descriptive system (EQ-5D)
representing the “societal value” of the patient’s current
health state. This part describes generic QoL based on 5
dimensions of health (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression) with responses
at 5 levels (no problems, slight problems, moderate
problems, severe problems, and unable to/extreme
problems). The index score, which is expressed on a
scale from 0 (death) to 1 (perfect health), is calculated
by matching the pattern of the 5 responses against a spe-
cific set of utilities derived from the Dutch population.31
The second part of the EQ-5D-5L represents the
patient’s perspective and consists of a EuroQoL self-
rated visual analogue scale (EQ-VAS) ranging from
0 (worst imaginable health state) to 100 (best imaginable
health state).www.giejournal.org
Dang et al Patient-reported impact of different treatment options for T1 CRCWe evaluated disease-specific QoL with the validated
Dutch version of the European Organization for Research
and Treatment 30-item Core Quality of Life Questionnaire
(EORTC QLQ-C30).32 This cancer-specific questionnaire
uses a 1-week time frame and includes 30 items that are lin-
early converted into a global health status score, 5 func-
tional scales (physical, role, emotional, cognitive, and
social functioning), 3 symptom scales (fatigue, nausea and
vomiting, and pain), and 6 individual symptom scores (dys-
pnea, insomnia, appetite loss, constipation, diarrhea, and
financial difficulties). The scores range from 0 to 100. A
higher score on the functional scales and the global health
status indicates a better QoL, whereas a higher score on the
symptom scales indicates a higher severity of symptoms.
Fear of cancer recurrence
We measured fear of cancer recurrence using the Dutch
translation of the validated Cancer Worry Scale (CWS).33-36
This instrument evaluates patients’ judged risk of cancer
recurrence, the frequency and degree of their worry, and
the impact of these concerns on daily functioning. The
CWS, which does not use a specific time frame, consists
of 4 questions with a 10-point Likert scale. These answer
scores are summed to calculate the overall CWS score,
which ranges from 0 to 40. A higher score indicates
more fear of cancer recurrence.
Subjective time to recovery
In both treatment groups, the patient’s perceived time
to recovery was evaluated with the following question:
“How long after the treatment for the malignant polyp
did you feel completely recovered?” Patients were re-
quested to indicate this period with an exact amount of
days, weeks, or months.
Procedure
In each participating center, all questionnaires were
sent once and on the same date to the patients’ home ad-
dresses along with a stamped return envelope. Patients
who did not return the questionnaire within 2 weeks
were contacted by phone to confirm the receipt of the
questionnaire and to check whether they were still willing
to participate.
Statistical analysis
Nominal and ordinal variables were expressed as fre-
quencies and percentages and continuous variables as
means and standard deviations. The Pearson c2 or the
Fisher exact test was used to compare categorical data,
as appropriate. Continuous variables were compared using
the Mann-Whitney U test.
We used multivariate linear regression to compare the
EQ-5D-5L, EORTC QLQ-C30, and CWS scores of endo-
scopically and surgically treated patients. The analyses
were adjusted for confounding variables, which were
selected according to the criteria of Rothman.37 Thewww.giejournal.orgfollowing variables were identified in the literature as
confounders: age and sex,2,38 body mass index and co-
morbidity,2,39 and family history of CRC.2,40 Because
the American Society of Anesthesiologists physical status
classification is mainly designed for the preoperative
setting,41 we chose to include the Charlson
Comorbidity Index in the regression analyses as an
indicator for patient comorbidity.
Furthermore, to explore the short-term and long-term
effects on the study outcomes of both treatments, we strat-
ified the aforementioned analyses on the time between
treatment date and moment of filling in the questionnaire.
The median time of the whole study population was used
as an a priori cut-off for division into 2 groups (short and
long term) to create treatment groups of comparable size
and to minimalize power reduction of these subgroup
analyses.
Additionally, another subgroup analysis was conducted to
investigate the influence of timing of surgery (ie, whether sur-
gery was performed as primary treatment or performed after
endoscopic resection) on the study outcomes. We split up
the surgery group into primarily and secondarily operated pa-
tients and separately compared them with endoscopically
treated patients. Because TEM may have greater impact on
functional outcomes than other endoscopic resection
methods,42 we also performed a sensitivity analysis with all
TEM patients in the surgery group.
All statistical analyses were performed using IBM SPSS
statistics version 23.0 (Chicago, Ill). P < .05 was considered
statistically significant.RESULTS
In total, 119 patients fulfilled our selection criteria and thus
received a questionnaire (Fig. 1). Of these patients, 62
(52.1%) were treated only with an endoscopic resection. In
the surgery group (n Z 57), 29 patients were primarily
treated with surgery, whereas 28 patients underwent an
additional surgical resection after endoscopic treatment.
The response rate was 88.7% (55/62) in the endoscopy
group and 96.5% (55/57) in the surgery group. In
both treatment groups, nonresponders did not give a
reason for not participating in this study. There were no
clinically relevant differences between responders and
nonresponders (data not shown, available on request).
With regard to demographic characteristics of the pa-
tients who responded, no significant differences were
found between the endoscopic and surgical treatment
groups (Table 1). Because the Dutch Bowel Cancer
Screening Programme exclusively targets people between
55 and 75 years old, both groups mainly consisted of
elderly, retired people.
Clinical and tumor characteristics are shown in
Tables 2 and 3, respectively. Figure 2 shows an

























Figure 1. Flowchart of patient selection in the 2 participating centers.
Patient-reported impact of different treatment options for T1 CRC Dang et alincluded patients. In the endoscopy group, 6 patients
received additional local treatment of the scar because
of suspected incomplete tumor removal. The median
time between primary and secondary endoscopic resec-
tion was 49.5 days (interquartile range, 34-80).
Endoscopy-related adverse events mainly included post-
procedural bleeding (n Z 5) or postpolypectomy coagu-
lation syndrome (n Z 2). Six patients actively rejected
surgery even though the treating clinician recommen-
ded an additional surgical resection. The median interval
between endoscopic resection and secondary surgery
was 55 days (interquartile range, 40-78). Reasons for sec-
ondary referral to the surgeon were the presence of
high-risk histologic features (n Z 14) or suspected
incomplete endoscopic tumor removal (n Z 13). None
of the surgically treated patients had LNM. Of all 12 pa-
tients with postoperative adverse events, 3 underwent
surgery again because of fascial dehiscence (n Z 1),
anastomotic stricture (n Z 1), or leakage (n Z 1). The
patient with an anastomotic stricture also received a per-
manent stoma after the reoperation. None of the pa-
tients had recurrent disease at time of filling in the
questionnaire.
Figures 3 and 4 show that the intervals between
treatment and moment of filling in the questionnaire
were comparable in the 2 treatment groups (endoscopy,
median 18 months, vs surgery, median 21 months; P Z
.157). The median duration of this interval for the whole
study population was 19 months. Using this cut-off value,
we divided all patients into a short-term (endoscopy,
n Z 28; surgery, n Z 24) and long-term (endoscopy,
n Z 27; surgery, n Z 31) stratum.
Global QoL, functioning, and symptom scores
According to the EQ-5D-5L, generic QoL from both
the patients’ and societal perspective was not signifi-536 GASTROINTESTINAL ENDOSCOPY Volume 89, No. 3 : 2019cantly different between the 2 treatment groups
(Table 4). The disease-specific EORTC QLQ-C30 also
did not show any difference in global health status and
general functioning. Furthermore, symptom scores
were comparable between the surgery and endoscopy
groups (Table 5). The subgroup analysis with the
separated surgery groups did not yield any differences
in all aforementioned outcomes (data not shown;
available on request). Similar results were also found in
stratified analyses (data not shown; available on
request), except for the short-term EQ-5D utility score
(endoscopy, .89, vs surgery, .93; P Z .034).
Fear of cancer recurrence
The results of the CWS are depicted in Table 6.
Endoscopically treated patients did not report more fear of
cancer recurrence than surgically treated ones (endoscopy,
7.6, vs surgery, 9.7; P Z .140). Stratification on time
between treatment and moment of measurement
showed that short-term (endoscopy, 7.9, vs surgery,
9.4; P Z .606) and long-term (endoscopy, 7.2, vs sur-
gery, 10.0; P Z .192) fear of cancer recurrence also
did not significantly differ between the treatment
groups. However, subgroup analysis showed that when
compared with the endoscopy group, primarily operated
patients reported significantly more fear of cancer recur-
rence (endoscopy, 7.6, vs primary surgery, 10.9; P Z
.025) but secondarily operated patients did not (endos-
copy, 7.6, vs secondary surgery, 8.5; P Z .789).
Subjective time to recovery
Responses to the question about the perceived time to re-
covery showed that recovery in endoscopically treated pa-
tients was 3 months faster than surgically treated patients.
With correction for all confounding variables, this difference
was strongly significant (P Z .001). This result was notwww.giejournal.org
TABLE 1. Demographic characteristics of the patients included in the analyses (n [ 110)
Endoscopic treatment (n [ 55) Surgery (n [ 55) P value
Mean age, y (SD) 68.7 (5.9) 69.0 (4.8) .584
Sex, male 37 (67.2) 35 (63.6) .841
Mean body mass index, kg/m2 (SD) 27.5 (4.0) 28.33 (4.5) .377
Marital status .351
Unmarried/single 1 (1.8) 4 (7.3)
Married/cohabiting 48 (87.3) 43 (78.2)
Divorced 3 (5.5) 2 (3.6)
Widowed 3 (5.5) 6 (10.9)
Employment status .882
Employed 17 (30.9) 15 (27.3)
<20 working hours per week 2 5
20-30 working hours per week 3 3
30-40 working hours per week 5 6
>40 working hours per week 7 1
Unemployed 4 (7.3) 5 (9.1)
Retired 34 (61.8) 35 (63.6)
ASA score .113
I 11 (20.0) 13 (23.6)
II 43 (78.2) 36 (65.5)
III 1 (1.8) 6 (10.9)
Mean Charlson Comorbidity Index (SD) 1.4 (1.5) 1.4 (1.7) .917
Abdominal surgery before CRC treatment 18 (32.7) 18 (32.7) 1.000
Positive family history of CRC 14 (25.5) 19 (34.5) .406
Values are n (%) unless otherwise defined.
ASA, American Society of Anesthesiologists physical status classification system; CRC, colorectal cancer; SD, standard deviation.
Dang et al Patient-reported impact of different treatment options for T1 CRCinfluenced by the time between treatment and questionnaire
completion because similar differences were observed in the
short term (endoscopy, 14 days, vs surgery, 76 days; P Z
.014) and long term (endoscopy, 26 days, vs surgery, 138
days; P Z .019) after treatment. The subgroup analysis
with the separated surgery groups also yielded comparable
results (endoscopy, 19.9 days, vs primary surgery, 142.9
days, P < 0.001; and endoscopy, 19.9 days, vs secondary sur-
gery, 78.6 days, P Z .011).
Sensitivity analysis
The sensitivity analysis with all patients treated with
TEM (n Z 6) in the surgery group showed similar results
on all study outcomes in all aforementioned analyses
(data not shown; available on request).DISCUSSION
Our study showed that the QoL (ie, global health status,
functioning and severity of symptoms), as measured with
the EORTC QLQ-C30 and EQ-5D-5L, was comparable in
endoscopically and surgically treated patients. Yet, thewww.giejournal.orgperceived recovery time of endoscopically treated patients
was 3 months shorter than that of the surgically treated pa-
tients. Furthermore, the endoscopy group did not report
more fear of cancer recurrence than the surgery group.
To our knowledge, this is the first study to provide empir-
ical data on treatment impact from the T1 CRC patient’s
perspective.
The results of the CWS may have come as a surprise,
because similarly designed studies of early-stage neo-
plasms in the upper GI tract (early gastric cancer43 and
Barrett’s esophagus36,44) reported that therapeutic endos-
copy is associated with a significantly higher degree of
fear of cancer recurrence than surgery. This difference
was mainly attributed to the more intensive follow-up pro-
gram, which was offered to endoscopically treated pa-
tients. In our study, however, the endoscopy group also
received a strict follow-up consisting of multiple surveil-
lance endoscopies, whereas the surgery group in general
was followed up with occasional abdominal and chest im-
aging. We propose several other hypotheses that may
have contributed to or explained this finding. First, 6 pa-
tients actively refused surgical treatment, despite it being
recommended by their treating clinician. This could haveVolume 89, No. 3 : 2019 GASTROINTESTINAL ENDOSCOPY 537
TABLE 2. Clinical characteristics of the patients included in the analyses (n [ 110)
Endoscopic treatment (n [ 55) Surgery (n [ 55) P value
Primary treatment
Endoscopic treatment 55 (100) 26 (47.3)
En-bloc snaring 21 (38.2) 5 (9.1)
Piecemeal snaring 1 (1.8) 2 (3.6)
En-bloc endoscopic mucosal resection 24 (43.6) 12 (21.8)
Piecemeal endoscopic mucosal resection 5 (9.1) 7 (12.7)
Endoscopic submucosal dissection 1 (1.8) 0 (.0)
TEM* 3 (5.5) 0 (.0)
Surgery NA 29 (52.7)
Right hemicolectomy 10 (18.2)
Left hemicolectomy 4 (7.3)
Low anterior resection 4 (7.3)
Sigmoidectomy 11 (20.0)
Secondary treatment
Endoscopic treatment 6 (10.9) NA
Endoscopic full-thickness resection 3 (5.5)
TEM* 3 (5.5)
Surgery NA 26 (47.3)
Left hemicolectomy 2 (3.6)





Yes 8 (14.5) 1 (1.8)









At 3 months follow-upx 31 (56.4)
At 9 months follow-upx 21 (38.2) NA
At 12 months follow-upx 6 (10.9) 20 (36.4)
Abdominal imaging performed 10 (18.2) 20 (36.4) .053
Chest imaging performed 5 (9.1) 20 (36.4) .001
Values are n (%). Significant values (P < .05) are in bold.
TEM, Transanal endoscopic microsurgery; NA, not applicable; T1 CRC, early invasive colorectal cancer.
*Patients treated with TEM underwent a local excision of the tumor without lymph node dissection and are therefore considered as endoscopically treated patients.
yRight-sided hemicolectomy (n Z 1), rectosigmoid resection (n Z 1), transverse resection (n Z 1), and segmental resection of the colon descendens (n Z 1).
zAfter radical endoscopic resection of T1 CRC, the Dutch guidelines recommend to perform surveillance colonoscopies at 3 and 9 months of follow-up, followed by routine
surveillance according to the guidelines after surgery for T1 CRC. After surgical resection of T1 CRC, the guidelines recommend to perform a surveillance colonoscopy 12 months
of follow-up and then with an interval of 3-5 years.51
xWith 2 months margin. Only surveillance endoscopies scheduled according to the guidelines (ie, endoscopy group, first surveillance endoscopy at 3 months, second at 9
months, and third at 12 months; surgery group, first surveillance endoscopy at 12 months) are counted.
538 GASTROINTESTINAL ENDOSCOPY Volume 89, No. 3 : 2019 www.giejournal.org
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TABLE 3. Tumor characteristics of the patients included in the analyses (n [ 110)
Endoscopic treatment (n [ 55) Surgery (n [ 55) P value
Tumor characteristics
Location .004
Right colon segment 1 (1.8) 12 (21.8)
Left colon segment 42 (76.4) 36 (65.5)
Rectum 12 (21.8) 7 (12.7)
Morphology <.001
Sessile 19 (34.5) 28 (50.9)
Flat 5 (9.1) 8 (14.5)
Pedunculated 31 (56.4) 11 (20.0)
Semi-pedunculated 0 (.0) 1 (1.8)
Missing 0 (.0) 7 (12.7)
Mean tumor size (SD) 20.5 (10.2) 19.3 (9.5) .524
Missing 3 (5.5) 4 (7.3)
Histology
Resection margins .803
Free 45 (81.8) 44 (80.0)
Not free 6 (10.9) 8 (14.5)
Not assessable 4 (7.3) 3 (5.5)
Differentiation grade .172
Well/intermediate 51 (92.7) 51 (92.7)
Poor 0 (0.0) 3 (5.5)
Mucinous 3 (5.5) 1 (1.8)
Missing 1 (1.8) 0 (.0)
Invasion depth Haggitt level 4 or more than Kikuchi Sm2 12 (21.8) 15 (27.3) <.001
Missing invasion depth 8 (14.5) 34 (61.8)
Lymphangio invasion 5 (9.1) 6 (10.9) 1.000
Retrieved lymph nodes 10 NA 37 (69.1)
Patients with 1 high-risk feature of LNM* 19 (34.5) 26 (47.3) <.001
Unknown LNM risk because of missing features 7 (12.7) 28 (50.9)
Values are n (%) unless otherwise defined. Significant values (P < .05) are in bold.
LNM, Lymph node metastasis; SD, standard deviation; NA, not applicable.
*High-risk features include deep submucosal invasion (Haggitt level 4 or Kikuchi level Sm2 or 3), positive resection margins, poor differentiation, and presence of lymphatic or
vascular invasion. Budding was not taken into account because the Dutch guideline does not recognize the presence of budding as a high-risk feature.51
Dang et al Patient-reported impact of different treatment options for T1 CRCled to less fear of cancer recurrence because these patients
may have accepted the potential negative consequences of
their decision. The relatively low CWS scores of these 6 pa-
tients also supported this hypothesis (median, 4.5; range,
0-9). Second, endoscopically treated T1 CRC patients
may have a different view on the strict follow-up. Today,
T1 CRC cases are often detected with population-based
screening programs.1 Participants of such screening
programs generally show more health-seeking behavior45
and may be comforted by frequent doctor visits and
intensive surveillance. Third, surgery for T1 CRC may not
lead to a greater sense of security than endoscopic
treatment. For early gastric and esophageal cancer, it is
believed that surgically treated patients had less fear of
cancer recurrence because they were more likely towww.giejournal.orgbelieve that all potential recurrence sites had been
removed.36,43,44 However, this does not apply to T1 CRC
patients, because surgical treatment for T1 CRC only in-
volves a partial removal of the large bowel in general.2 In
fact, depending on the timing of the resection, surgery
may even cause more fear of cancer recurrence. Our
subgroup analysis showed that primarily operated
patients had significantly higher CWS scores than
endoscopically treated patients, possibly because they had
the feeling that their disease was so serious that it could
not be treated endoscopically. However, when surgery is
additionally performed after endoscopic tumor resection,
patients do not report more fear of cancer recurrence. It
seems that these patients are more likely to view their
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Figure 2. Overview of therapeutic decision-making of all T1 CRC patients who responded to the questionnaire (n Z 110).
*The median time interval between initial and second endoscopy was 43.5 days (interquartile range, 28-89). **The median time interval between initial
colonoscopy and primary surgical resection was 34.5 days (interquartile range, 29-56). ***Because of tumor location (n Z 1), multiple polyps (n Z 1),
and high adverse event risk estimated if performing endoscopic resection (n Z 1).
T1 CRC, Early invasive colorectal cancer; LNM, lymph node metastasis.


















Figure 3. Time in months between treatment and moment of filling in the questionnaire, endoscopic treatment (median, 18; interquartile range, 9-26.5).
Patient-reported impact of different treatment options for T1 CRC Dang et alwas adequately treated or cured. Last, an additional local scar
resection was performed in 6 endoscopically treated patients:
this additional therapy may have further reassured them
about the curative potential of their endoscopic treatment.
However, no support for this hypothesis can be found in
their CWS scores (median, 9; range, 3-13).
In contrast to similar studies in early upper tract neo-
plasms,36,43,44 QoL did not favor endoscopic treatment
compared with surgery in T1 CRC patients, despite that540 GASTROINTESTINAL ENDOSCOPY Volume 89, No. 3 : 2019endoscopic resection is much less invasive. Instead, the
faster recovery essentially favors endoscopic tumor resec-
tion from the patient’s perspective.
Although self-perceived global QoL status (EuroQoL
self-rated visual analogue scale and EORTC QLQ-C30 global
health status scores) did not significantly differ, the short-
term societal value of patients’ health state (EQ-5D score)
of the endoscopy group was lower than that of the surgery


















Figure 4. Time in months between treatment and moment of filling in the questionnaire, surgery (median, 21; interquartile range, 14-27).
TABLE 4. EQ-5D-5L and EORTC QLQ-C30 functional scores
Endoscopic treatment (n [ 55) Surgery (n [ 55) Mean difference P value*
EORTC QLQ-C30 functional scales (range, 0-100)
Global health status 84.4 (14.2) 83.8 (14.6) þ.6 .826
Physical functioning 92.0 (11.3) 91.6 (12.3) þ.4 .873
Role functioning 89.7 (20.7) 92.4 (15.3) –2.7 .346
Emotional functioning 90.8 (15.2) 87.7 (14.2) þ3.0 .271
Cognitive functioning 91.8 (16.0) 94.5 (11.6) –2.7 .256
Social functioning 94.8 (13.9) 92.7 (16.3) þ2.1 .640
EQ-5D-5L
EQ-VAS (range, 0-100) 84.1 (11.7) 85.2 (12.5) –1.2 .659
EQ-5D (range, 0-1) .88 (.11) .90 (.09) –.02 .284
Values are mean (standard deviation). The EQ-VAS and EQ-5D represent quality of life from the patient’s and societal perspective, respectively.
EORTC QLQ-C30, European Organization for Research and Treatment 30-item Core Quality of Life Questionnaire; EQ-5D-5L, 5-level EuroQoL 5-dimension questionnaire; EQ-VAS,
EuroQoL self-rated visual analogue scale; EQ-5D, EuroQoL 5-item descriptive system.
*Multivariate analysis controls for age, sex, body mass index, Charlson Comorbidity Index, and family history of colorectal cancer.
Dang et al Patient-reported impact of different treatment options for T1 CRCsocietal and the patient’s perspective may indicate rela-
tively lower health expectations in endoscopically treated
patients, this may also explain the faster recovery
perceived by them. However, despite statistical signifi-
cance, the magnitude of the difference on the short-term
EQ-5D was not considered to be clinically relevant (ie,
.07-.12 points),46 suggesting that this explanation is
unlikely. Alternatively, we believe that the faster
recovery is more likely to be explained by the superior
QoL directly after endoscopic treatment for T1 CRC. A
prospective study comparing patient-reported QoL of
endoscopic submucosal dissection with laparoscopic co-
lectomy at 14 days after treatment concluded that endo-
scopic submucosal dissection provided a significantly
better QoL than colectomy.47
However, such difference in QoL seems to disappear af-
ter a longer period of time. In our study, which had a me-
dian interval of 19 months between treatment and
questionnaire completion, neither significant nor clinically
relevant differences on the EORTC QLQ-C30 and EQ-5D-5Lwww.giejournal.orgwere found between the 2 treatment groups. These results
corroborate 2 previous studies reporting that QoL of pa-
tients treated with total mesorectal excision or TEM was
comparable from 1 year after treatment.48,49
Our hypothesis is that the impact of both surgical and
endoscopic T1 CRC treatment does not exceed the range
of patients’ adaptability or resilience. In other words, a
possible difference in treatment impact may only influence
the QoL shortly after treatment. However, such influence
may be masked after a longer period of time, when pa-
tients have adapted themselves to their new condition or
have restored their QoL.
The clinical implications of our study results can mainly
be sought in providing quantitative measures of relevant
patient-reported outcomes. These can be integrated in
the process of therapeutic decision-making, especially in
the absence of a clear indication for surgical or endoscopic
treatment. As we can deduce from our data, therapeutic
decision-making in T1 CRC patients remains challenging
in Dutch daily practice. For example, suspectedVolume 89, No. 3 : 2019 GASTROINTESTINAL ENDOSCOPY 541
TABLE 6. Fear of cancer recurrence and subjective time to recovery
Endoscopic treatment (n [ 55) Surgery (n [ 55) Mean difference P value*
Cancer Worry Scale (range, 0-40) 7.6 (4.5) 9.7 (8.2) –2.2 .140
Patients’ perceived time to recovery in days 19.9 (50.6) 111.3 (179.5) –91.5 .001
Values are mean (standard deviation). Significant values (P < .05) are in bold.
*Multivariate analysis controls for age, sex, body mass index, Charlson Comorbidity Index, and family history of colorectal cancer.
TABLE 5. EORTC QLQ-C30 symptom scores
Endoscopic treatment (n [ 55) Surgery (n [ 55) Mean difference P value*
EORTC QLQ-C30 symptom scales (range, 0-100)
Fatigue 11.3 (17.7) 14.3 (18.4) –3.0 .498
Nausea and vomiting 3.3 (10.8) 3.6 (11.0) –.3 .855
Pain 10.0 (18.9) 9.7 (18.6) þ.3 .734
Dyspnea 8.5 (16.0) 10.3 (19.1) –1.8 .868
Insomnia 13.3 (19.9) 14.5 (22.9) –1.2 .967
Appetite loss 4.8 (16.3) 3.6 (12.3) þ1.2 .596
Constipation 5.5 (14.0) 9.7 (21.9) –4.2 .313
Diarrhea 7.3 (18.9) 5.5 (14.0) þ1.8 .533
Financial difficulties 2.4 (10.8) 3.0 (11.6) –.6 .752
Values are mean (standard deviation).
EORTC QLQ-C30, European Organization for Research and Treatment 30-item Core Quality of Life Questionnaire.
*Multivariate analysis controls for age, sex, body mass index, Charlson Comorbidity Index, and family history of colorectal cancer.
Patient-reported impact of different treatment options for T1 CRC Dang et alincomplete tumor removal led to an additional scar resec-
tion in 6 patients, whereas 13 other patients underwent
surgery for the same reason. In most cases with a histologic
high-risk feature in the endoscopy group, it was unclear
why these patients did not receive an additional resection.
Furthermore, all additional treatments actually performed
after endoscopic resection did not provide additional
oncologic benefit because no residual cancer cells or
LNM were found. This illustrates the limitations of the cur-
rent decision-making model in T1 CRC, which mainly fo-
cuses on preventing under-treatment but leads to a large
amount of resections with suboptimal benefit. Given these
limitations, we strongly stress the importance of eliciting
the patient’s perspective in therapeutic decision-making
for T1 CRC.
Several strengths of our study merit attention. First, the
overall response rate was relatively high (92.4%), conse-
quently minimizing the risk of selection bias. Second, all
questionnaires included in this study have been validated
and are widely used. Third, by including as many prede-
fined confounders as possible, we reduced the possibility
of confounding by indication and increased the likelihood
that eventual outcome differences could be attributed to a
specific treatment. Finally, this is the first study in T1 CRC
patients that compares QoL, fear of cancer recurrence, and
perceived time to recovery after endoscopic and surgical
tumor resection.
Several limitations of this study should also be
mentioned. First, the time between treatment and date542 GASTROINTESTINAL ENDOSCOPY Volume 89, No. 3 : 2019of filling in the questionnaire varied considerably in this
study population. Although the average interval did not
significantly differ between the 2 treatment groups, we
stratified our analyses by time between treatment and
questionnaire completion to explore the influence of this
important effect modifier on the study outcomes. Second,
extrapolation of our results to other T1 CRC patients may
be hampered because, for practical reasons, the study pop-
ulation exclusively consisted of participants of the Dutch
Bowel Cancer Screening Programme. Because of the
healthy user effect,50 screening-detected T1 CRC cases
may not represent the average T1 CRC patient population.
Third, for practical reasons, it was not possible to take into
account the variety of treating physicians. This may have
biased our results because personal characteristics and
communication style of physicians, for example, can influ-
ence patients’ health perceptions. Finally, and also most
importantly, the cross-sectional study design limits the val-
idity of our results. For example, it was not possible to
measure QoL or fear of cancer recurrence of patients at
baseline or prospectively at multiple time points in the
follow-up. Given these limitations, we consider this study
to be exploratory and as a starting point for prospective,
longitudinal studies.
In summary, this study showed that endoscopically
treated T1 CRC patients perceived 3 months faster recov-
ery than surgically treated ones. Moreover, the endoscopy
group did not report worse QoL or more fear of cancer
recurrence than the surgery group. Because patient-www.giejournal.org
Dang et al Patient-reported impact of different treatment options for T1 CRCreported outcomes are becoming increasingly important in
cancer care, the results of this study contribute to the
shared therapeutic decision-making process of clinicians
and T1 CRC patients.ACKNOWLEDGMENTS
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